Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”
This article was originally published in The Gray Sheet
Executive Summary
Medtronic recently announced FDA approval of its MiniMed 530G low-glucose-suspend insulin pump, the first system approved in the U.S. that can automatically stop insulin delivery when blood glucose levels fall to a pre-set level.
You may also be interested in...
Tandem Diabetes Adds Special Touch (Screen) To Integrated Pump-Monitor Space
Tandem Diabetes Care’s t:slim G4 insulin pump/continuous glucose monitor system is the latest DexCom partnership to yield an FDA approval, and the first integrated diabetes system to feature a touch-screen display.
Medtronic Launches Predictive MiniMed 640G Insulin Pump Outside The U.S.
The company touts the system as its latest breakthrough toward the development of an artificial pancreas. It can automatically suspend or resume insulin delivery based on pre-set thresholds.
Medtronic Launches U.S. Trial For Predictive Glucose Monitor-Pump System
The single-arm pivotal trial is assessing the firm's next-generation diabetes system, which adds predictive algorithm features and a smaller sensor compared to the currently marketed MiniMed 530G low-glucose suspend device, marking another step towards an artificial pancreas, Medtronic says.